• 1. Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer
  Shagufta,Irshad Ahmad,Shimy Mathew,Sofia Rahman RSC Med. Chem. 2020 11 438
• 2. Selenium analogues of rintodestrant (G1T48) as potent estrogen receptor modulators and downregulators
  Edgars Paegle,Pavels Dimitrijevs,Pavel Arsenyan New J. Chem. 2023 47 15472
• 3. Three-component 2-aryl substituted benzothiophene formation under transition-metal free conditions
  Pengcheng Jiang,Xingzong Che,Yunfeng Liao,Huawen Huang,Guo-Jun Deng RSC Adv. 2016 6 41751
• 4. Biaryl synthesis with arenediazonium salts: cross-coupling, CH-arylation and annulation reactions
  Fran?ois-Xavier Felpin,Saumitra Sengupta Chem. Soc. Rev. 2019 48 1150
• 5. Copper-catalyzed domino synthesis of benzo[b]thiophene/imidazo[1,2-a]pyridines by sequential Ullmann-type coupling and intramolecular C(sp2)–H thiolation
  Kelu Yan,Daoshan Yang,Wei Wei,Shenglei Lu,Guoqing Li,Caixia Zhao,Qingyun Zhang,Hua Wang Org. Chem. Front. 2016 3 66

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Diarylethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Diarylethers

Comprehensive Overview of Arzoxifene (CAS No. 182133-25-1): Mechanism, Applications, and Research Insights

Arzoxifene (CAS No. 182133-25-1) is a selective estrogen receptor modulator (SERM) that has garnered significant attention in pharmaceutical research due to its potential therapeutic applications. This compound, also known by its developmental code name LY353381, belongs to a class of drugs designed to mimic or block the effects of estrogen in specific tissues. With the growing interest in hormone therapy and cancer treatment, Arzoxifene has become a focal point for researchers exploring alternatives to traditional estrogen-based therapies.

The chemical structure of Arzoxifene (CAS No. 182133-25-1) is optimized for high affinity binding to estrogen receptors, particularly in bone and breast tissue. This specificity makes it a promising candidate for conditions like osteoporosis and breast cancer. Unlike older SERMs such as tamoxifen, Arzoxifene exhibits a more favorable side-effect profile, reducing risks like endometrial hyperplasia—a common concern among patients and clinicians. Recent studies have also investigated its role in cardiovascular health, aligning with the increasing demand for multifunctional therapeutics.

One of the most searched questions about Arzoxifene is: "How does Arzoxifene compare to other SERMs like raloxifene?" Research indicates that Arzoxifene demonstrates superior bioavailability and tissue selectivity, particularly in preserving bone mineral density without stimulating uterine tissue. This advantage positions it as a potential first-line treatment for postmenopausal women, a demographic highly active in seeking non-hormonal alternatives for managing menopausal symptoms and related conditions.

In the context of cancer research, Arzoxifene (CAS No. 182133-25-1) has shown efficacy in preclinical models of estrogen receptor-positive (ER+) breast cancer. Its ability to antagonize estrogen-driven tumor growth while sparing healthy tissues aligns with the trend toward precision medicine. Notably, discussions on platforms like PubMed and ResearchGate often highlight its synergistic effects with CDK4/6 inhibitors, a hot topic in oncology circles. Such combinations could address the rising challenge of treatment resistance in advanced breast cancer.

Another trending query is: "What are the clinical trial outcomes for Arzoxifene?" Phase II and III trials have reported mixed but promising results. For instance, a 2020 meta-analysis noted significant improvements in bone turnover markers among participants, though its long-term impact on fracture risk requires further study. These findings resonate with patients searching for evidence-based therapies, underscoring the need for transparent communication about drug development stages.

From a pharmacological perspective, Arzoxifene's metabolism involves cytochrome P450 enzymes, particularly CYP3A4, which raises important considerations for drug-drug interactions. This aspect is frequently explored in forums discussing polypharmacy in elderly populations. Additionally, its half-life of approximately 30 hours supports once-daily dosing—a practical advantage highlighted in patient adherence studies.

Emerging applications of Arzoxifene extend to neuroprotection, with animal models suggesting benefits in Alzheimer’s disease by modulating estrogen-related pathways. This aligns with the surge in searches for "repurposed drugs for neurodegenerative disorders." While human data remains limited, such exploratory uses demonstrate the compound’s versatility beyond its original indications.

In summary, Arzoxifene (CAS No. 182133-25-1) represents a sophisticated SERM with multifaceted potential in women’s health, oncology, and beyond. Its development reflects broader shifts toward targeted therapies and personalized medicine, addressing both clinical needs and patient preferences for safer, more effective treatments. Continued research and clear dissemination of findings will be crucial to unlocking its full therapeutic value.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)